Climb Bio Inc
CLYM1.696USD
+0.246+16.99%
Horário de mercado （ET）Cotações atrasadas em 15 min
114.63MValor de mercado
PerdaP/L TTM
Mais detalhes de Climb Bio Inc Empresa
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
Informações da empresa
Código da empresaCLYM
Nome da EmpresaClimb Bio Inc
Data de listagemAug 10, 2021
CEODr. Aoife M. Brennan
Número de funcionários17
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 10
Endereço20 William Street
CidadeWELLESLEY HILLS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02481
Telefone18668572596
Sitehttps://climbbio.com/
Código da empresaCLYM
Data de listagemAug 10, 2021
CEODr. Aoife M. Brennan
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Investidores
Investidores
Proporção
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Tipos de investidores
Investidores
Proporção
Venture Capital
54.93%
Investment Advisor
12.36%
Hedge Fund
11.49%
Corporation
7.41%
Research Firm
3.67%
Investment Advisor/Hedge Fund
2.47%
Individual Investor
0.67%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
6.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
168
62.90M
93.07%
-4.49M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
BlackRock Institutional Trust Company, N.A.
2.10M
3.1%
-10.56K
-0.50%
Mar 31, 2025
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
Ver Mais
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
iShares Micro-Cap ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
iShares Neuroscience and Healthcare ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
